.jpg)
Backing from BioNTech powers ADC specialist DualityBio toward $200M Hong Kong IPO
Duality Biologics has begun offering stock, wading into a market routed by Trump’s tariffs in pursuit of up to 1.56 billion Hong Kong dollars ($200 million) to fund its antibody-drug conjugate pipeline. Backers including BioNTech have committed around one-third of the targeted IPO haul.
Duality Biologics has begun offering stock, wading into a market routed by Trump’s tariffs in pursuit of up to 1.56 billion Hong Kong dollars ($200 million) to fund its antibody-drug conjugate pipeline. Backers including BioNTech have committed around one-third of the targeted IPO haul.
